Mega Lifesciences Current Valuation vs. Return On Equity
| MEGA Stock | THB 35.25 0.25 0.70% |
For Mega Lifesciences profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Mega Lifesciences to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Mega Lifesciences Public utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Mega Lifesciences's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Mega Lifesciences Public over time as well as its relative position and ranking within its peers.
Mega |
Mega Lifesciences Public Return On Equity vs. Current Valuation Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Mega Lifesciences's current stock value. Our valuation model uses many indicators to compare Mega Lifesciences value to that of its competitors to determine the firm's financial worth. Mega Lifesciences Public is regarded third in current valuation category among its peers. It is regarded second in return on equity category among its peers . The ratio of Current Valuation to Return On Equity for Mega Lifesciences Public is about 132,376,810,868 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Mega Lifesciences' earnings, one of the primary drivers of an investment's value.Mega Current Valuation vs. Competition
Mega Lifesciences Public is regarded third in current valuation category among its peers. After adjusting for long-term liabilities, total market size of Health Care industry is now estimated at about 1.19 Trillion. Mega Lifesciences holds roughly 38.59 Billion in current valuation claiming about 3% of equities under Health Care industry.
Mega Return On Equity vs. Current Valuation
Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Mega Lifesciences |
| = | 38.59 B |
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Mega Lifesciences |
| = | 0.29 |
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
Mega Return On Equity Comparison
Mega Lifesciences is currently under evaluation in return on equity category among its peers.
Mega Lifesciences Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Mega Lifesciences, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Mega Lifesciences will eventually generate negative long term returns. The profitability progress is the general direction of Mega Lifesciences' change in net profit over the period of time. It can combine multiple indicators of Mega Lifesciences, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Mega Lifesciences Public Company Limited, together with its subsidiaries, manufactures, markets, and sells health food supplements, prescription pharmaceutical products, over-the-counter products, herbal products, vitamins, and fast moving consumer goods. Mega Lifesciences Public Company Limited is a subsidiary of Unistretch Limited. MEGA LIFESCIENCES operates under Drug Manufacturers - Major classification in Thailand and is traded on Stock Exchange of Thailand.
Mega Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Mega Lifesciences. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Mega Lifesciences position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Mega Lifesciences' important profitability drivers and their relationship over time.
Use Mega Lifesciences in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Mega Lifesciences position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Mega Lifesciences will appreciate offsetting losses from the drop in the long position's value.Mega Lifesciences Pair Trading
Mega Lifesciences Public Pair Trading Analysis
The ability to find closely correlated positions to Mega Lifesciences could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Mega Lifesciences when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Mega Lifesciences - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Mega Lifesciences Public to buy it.
The correlation of Mega Lifesciences is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Mega Lifesciences moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Mega Lifesciences Public moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Mega Lifesciences can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Mega Lifesciences position
In addition to having Mega Lifesciences in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Aggressive Funds Thematic Idea Now
Aggressive Funds
Funds or Etfs that attempt to achieve high capital gains by investing in companies with high growth potential and above average risk. The Aggressive Funds theme has 45 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Aggressive Funds Theme or any other thematic opportunities.
| View All Next | Launch |
Other Information on Investing in Mega Stock
To fully project Mega Lifesciences' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Mega Lifesciences Public at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Mega Lifesciences' income statement, its balance sheet, and the statement of cash flows.